ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
MWN-AI** Summary
ImmuCell Corporation (Nasdaq: ICCC), a firm focused on animal health, has announced a strategic pivot in response to an Incomplete Letter received from the FDA regarding its Re-Tain® New Animal Drug Application (NADA). The FDA had previously granted Complete Letters for four of the five required Technical Sections but reported concerns over the inspectional deficiencies of a contract manufacturer involved in the product’s aseptic filling. Consequently, ImmuCell plans to halt investments in Re-Tain® while simultaneously expanding its First Defense® franchise by increasing its sales force by 50% and enhancing manufacturing capabilities.
President and CEO Olivier te Boekhorst emphasized the company’s commitment to its First Defense® products—proven to prevent scours in calves—which hold a substantial 29% market share in the U.S. for scour prevention. The firm believes further investment in this area aligns with its goal of maximizing shareholder value, particularly given the estimated $900 million total addressable market. To facilitate this shift, ImmuCell will repurpose existing facilities and equipment to bolster First Defense® production, which has demonstrated consistent annual growth.
Despite the setback with Re-Tain®, ImmuCell remains optimistic about the potential for new claims related to mastitis prevention and treatment, opting to either license the product or partner with a global manufacturer in the future. The company anticipates a non-cash impairment write-down associated with Re-Tain® due to adjustments in lab and manufacturing assets. First Defense® is positioned for continued growth, and ImmuCell intends to announce its revenue results for the quarter and year ending December 31, 2025, in early January 2026.
MWN-AI** Analysis
ImmuCell Corporation (Nasdaq: ICCC) has recently announced a strategic pivot following an FDA Incomplete Letter for its Re-Tain® product. This development is significant as ImmuCell plans to focus on expanding its First Defense® franchise, a product line that has been a market leader in preventing scours in calves. With a strong reputation and considerable market share in a $900 million total addressable market, this shift could potentially offer substantial revenue opportunities in the near term.
For investors, this strategic reallocation of resources suggests a positive outlook, particularly given First Defense®'s historical growth trajectory, which has averaged over 13% compounded annually for the past decade. ImmuCell's increased investment in First Defense®, including a 50% expansion of its field sales force and enhancements to manufacturing capabilities, positions the company to capture further market share domestically and internationally.
However, investors should be mindful of potential challenges in the form of a non-cash impairment write-down related to the Re-Tain® assets. This could impact short-term financials, with an expected effect of approximately $2.3 million. While such adjustments might raise concerns, ImmuCell's commitment to transitioning resources toward First Defense® significantly mitigates longer-term risks associated with the halted Re-Tain® project.
Overall, as ImmuCell navigates this transitional phase, the emphasis on bolstering First Defense® appears to be a strategic move aimed at maximizing shareholder value. Investors should watch for updates on revenue performance when the company announces financial results in early January. Given the strong market demand and the company's proactive steps to enhance product offerings, the investment potential in ImmuCell remains promising for those preparing for future growth in the animal health sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50% and expanding its First Defense® manufacturing capabilities.
In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It pursued a two-pronged manufacturing approach to reduce capital expenditure and limit technical risk for the remaining fifth Technical Section pertaining to manufacturing. ImmuCell manufactured the active pharmaceutical ingredient using a proprietary process in its own facility and hired an experienced contract manufacturer with FDA approvals for animal health products for the aseptic filling of the product into syringes. ImmuCell passed FDA inspection of its own facility in 2024. It is ImmuCell’s understanding that the FDA is now declining to approve the NADA because the contract manufacturer has not satisfactorily addressed inspectional deficiencies.
After considering the practical implications of the resulting delays, including the pending expiration of ImmuCell’s contract with the manufacturer in March 2026, ImmuCell has decided to pause further investment in Re-Tain® and increase its investment in its market leading First Defense® franchise, which it believes to have significant revenue and profit growth capacity.
ImmuCell will complete ongoing investigational studies with Re-Tain® to assess opportunities for an improved set of claims for preventing and treating mastitis in dairy cows. It will seek to license the product to interested parties or, depending on the outcome of the studies, may seek to partner with a global manufacturer. Neither approach would require further capital investment or in-house manufacturing capability, meaning that ImmuCell will prioritize cash and other resources for maximizing the value of its market leading First Defense® franchise.
“While it is disappointing news that we will be unable to achieve NADA approval with this contract manufacturer, this has only strengthened our resolve to allocate our resources to our highest return opportunity, namely First Defense®,” said Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell. “We will focus on maximizing our opportunities in the estimated $900 million worldwide Total Addressable Market for preventing scours in calves. Based on feedback from customers about our products and our ongoing internal assessment of potential manufacturing efficiencies, we believe there is significant runway for top-line growth and margin expansion for First Defense® that would drive sustainable profit growth for ImmuCell.”
ImmuCell’s First Defense® product line is based on proprietary colostrum hyper-immunization technology, offering a unique range of products with considerable growth potential. The brand holds strong leadership in the U.S. market, shown by its #1 ranking for scour-prevention in the 2025 Hoard’s Dairyman Continuing Market Study and its 29% share of U.S. spend on scours prevention, and targets a sector where high calf values present significant opportunities in dairy and beef industries. ImmuCell believes it is in a favorable position to expand sales internationally and to develop new products by harnessing the special antibody-rich and bioactive properties of colostrum.
“As a result of this strategic change in focus, ImmuCell expects to record a non-cash impairment write-down of property, plant and equipment during the fourth quarter of 2025. As previously disclosed, net book value of Re-Tain® assets was approximately $15.5 million as of September 30, 2025. We are anticipating adjustments to laboratory and manufacturing equipment and construction in progress, resulting in an estimated non-cash impact to profit of approximately $2.3 million. The final figure for this non-cash expense will be determined after a review of alternate purposing and net realizable value is completed as part of the financial closing for the quarter and year ending December 31, 2025,” says Timothy Fiori, Chief Financial Officer. “We plan to repurpose facilities and a large portion of the equipment for the expansion of First Defense® capacity to maximize return on these assets.”
“We are pleased to announce immediate steps toward First Defense® commercial and manufacturing expansion,” added Mr. te Boekhorst. “We have created two new sales territories in the U.S., and we are hiring a senior dairy executive to execute our international strategy. We have also started a multi-year manufacturing improvement program to lower product costs, improve manufacturing yields, and execute our next phase of capacity expansion. Customer feedback and our own market assessments give us confidence that this is the right time for further investment in First Defense®.”
David S. Tomsche, DVM, Chair of the ImmuCell Board of Directors, commented, “Fifteen years ago, ImmuCell established a small field team that grew First Defense® annual revenue from approximately $4.4 million then to approximately $27.8 million in the trailing twelve-month period ended September 30, 2025. First Defense®’s record of more than 13% compounded growth per year for more than a decade gives us confidence that focusing on and investing more in First Defense® can deliver strong shareholder value.”
ImmuCell expects to announce its topline revenue results for the quarter and year ending December 31, 2025 on Thursday, January 8, 2026. ImmuCell expects to host a conference call to discuss revenue results and certain balance sheet activities on Friday, January 9, 2026 at 9:00 AM ET. ImmuCell expects to announce its full financial results for the year ending December 31, 2025 on Wednesday, February 25, 2026. ImmuCell expects to host a conference call to discuss its financial results for the year ending December 31, 2025 on Thursday, February 26, 2026 at 9:00 AM ET.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; the expected timing of key future events; future operational performance and financial results; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. Such statements involve known and unknown risks and uncertainties that may cause ImmuCell’s actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
About ImmuCell:
ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves. Press releases and other information about ImmuCell are available at: http://www.immucell.com.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@ImmuCell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com |
FAQ**
How will the decision to pause further investment in ImmuCell Corporation ICCC's Re-Tain® affect its overall financial health and future growth potential?
What specific strategies will ImmuCell Corporation ICCC implement to expand the sales and manufacturing capabilities of its First Defense® product line?
Given the non-cash impairment write-down for Re-Tain®, how does ImmuCell Corporation ICCC plan to manage its assets to maximize returns?
How does ImmuCell Corporation ICCC assess the competitive landscape for its First Defense® products in both domestic and international markets moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about ImmuCell Corporation (NASDAQ: ICCC).
NASDAQ: ICCC
ICCC Trading
1.39% G/L:
$6.58 Last:
7,550 Volume:
$6.39 Open:
